Atomoxetine HCl

Catalog No.S3175 Synonyms: LY 139603 HCl

For research use only.

Atomoxetine (LY 139603) is a selective norepinephrine (NE) transporter inhibitor with Ki of 5 nM, with 15- and 290-fold lower affinity for human 5-HT and DA transporters.

Atomoxetine HCl Chemical Structure

CAS No. 82248-59-7

Purity & Quality Control

Choose Selective 5-HT Receptor Inhibitors

Other 5-HT Receptor Products

Biological Activity

Description Atomoxetine (LY 139603) is a selective norepinephrine (NE) transporter inhibitor with Ki of 5 nM, with 15- and 290-fold lower affinity for human 5-HT and DA transporters.
Targets
Norepinephrine (NE) transporter [1] 5-HT [1] DA transporter [1]
5 nM(Ki) 77 nM(Ki) 1451 nM(Ki)
In vitro

Atomoxetine is a selective norepinephrine reuptake inhibitor with Ki of 5 nM, compared with 77 and 1451 nM for binding to serotonin and dopamine transporters. [1]

In vivo In microdialysis studies, atomoxetine increases extracellular (EX) levels of NE in prefrontal cortex (PFC) 3-fold, but does not alter 5-HTEX levels. Atomoxetine also increases DAEX concentrations in PFC 3-fold, but does not alter DAEX in striatum or nucleus accumbens. Atomoxetine increases Fos by 3.7-fold in PFC, but not in the striatum or nucleus accumbens. [1] Atomoxetine selectively inhibits the presynaptic uptake of norepinephrine in adrenergic neurons in animals, and has activity in animal models of depression. [2][3]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 58 mg/mL
(198.75 mM)
Ethanol 37 mg/mL
(126.79 mM)
Water 2 mg/mL
(6.85 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 291.82
Formula

C17H21NO.HCl

CAS No. 82248-59-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05101122 Recruiting Drug: Dosing 1: Atomoxetine|Drug: Dosing 2-4: AD313 Obstructive Sleep Apnea Apnimed October 6 2021 Phase 1|Phase 2
NCT03460210 Recruiting Drug: Atomoxetine Obesity Morbid Norwegian University of Science and Technology|St. Olavs Hospital|Volvat Medisinsk Senter Stokkan|Namsos Hospital|Alesund Hospital November 2 2016 --
NCT01522404 Completed Drug: Atomoxetine|Drug: Placebo Mild Cognitive Impairment Emory University|National Institute on Aging (NIA) March 2012 Phase 2
NCT01709695 Completed Drug: Guanfacine Hydrochloride XR|Drug: Placebo ADHD|Attention Deficit Hyperactivity Disorder Icahn School of Medicine at Mount Sinai March 2011 Phase 4
NCT02014064 Completed Drug: Atomoxetine|Other: Placebo Continuous Methamphetamine Dependence|Methamphetamine Dependence in Remission University of California Los Angeles August 2009 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Atomoxetine HCl | Atomoxetine HCl supplier | purchase Atomoxetine HCl | Atomoxetine HCl cost | Atomoxetine HCl manufacturer | order Atomoxetine HCl | Atomoxetine HCl distributor